(Q37785721)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals (English)

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

bacterial drug resistance

7 July 2024

main subject

public health

0 references

antibiotic resistance

1 reference

based on heuristic

inferred from title

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820028

7 July 2024

reimbursement mechanisms

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820028

7 July 2024

1

Aaron S Kesselheim

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

23 August 2017

2

Kevin Outterson

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

13 February 2020

https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.2009.0439

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820028

http://www.healthaffairs.org/cgi/content/abstract/29/9/1689

7 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20820028

http://www.healthaffairs.org/doi/10.1377/hlthaff.2009.0439

7 July 2024

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

7 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1689-1696

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20820028%20AND%20SRC:MED&resulttype=core&format=json

Clinical and economic burden of antimicrobial resistance.

13 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

7 July 2024

Acinetobacter infection

2

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa

7 July 2024

3

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005

7 July 2024

4

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Cost of Gram-negative resistance

7 July 2024

5

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.

7 July 2024

6

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility

7 July 2024

7

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antibiotic-resistant bugs in the 21st century--a clinical super-challenge

7 July 2024

8

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antibiotic and antiseptic resistance: impact on public health

7 July 2024

9

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

The First Use of Penicillin in the United States

7 July 2024

10

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Staphylococcal infection due to penicillin-resistant strains

7 July 2024

11

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antibacterial resistance worldwide: causes, challenges and responses

7 July 2024

12

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Physician awareness and self-reported use of local and national guidelines for community-acquired pneumonia

7 July 2024

13

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

In tepid defense of population health: physicians and antibiotic resistance

7 July 2024

14

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

British Journal of General Practice

7 July 2024

15

56

183

Coenen S

2006

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

7 July 2024

16

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antibiotics: a shot in the arm

7 July 2024

17

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

The antibiotic pipeline--challenges, costs, and values

7 July 2024

18

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.

7 July 2024

19

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit.

7 July 2024

20

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use.

7 July 2024

21

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.

7 July 2024

22

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center

7 July 2024

23

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Do educational interventions improve management of patients with community-acquired pneumonia?

7 July 2024

24

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Hospital antibiotic stewardship

7 July 2024

25

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Nonpayment for harms resulting from medical care: catheter-associated urinary tract infections

7 July 2024

27

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Can better prescribing turn the tide of resistance?

7 July 2024

28

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Will longer antimicrobial patents improve global public health?

7 July 2024

31

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Wild-card patent extensions as a means to incentivize research and development of antibiotics.

7 July 2024

32

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

7 July 2024

35

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Progress and new directions in genetics of tuberculosis: an NHLBI working group report

7 July 2024

36

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

7 July 2024

37

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance

7 July 2024

38

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Antimicrobial drug development--the past, the present, and the future

7 July 2024

40

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Trends in development and approval times for new therapeutics in the United States

7 July 2024

42

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Clinical Infectious Diseases

7 July 2024

43

author name string

Outterson K

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

NICE proposes to withdraw Alzheimer's drugs from NHS.

7 July 2024

44

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439

Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia

7 July 2024

45

1 reference

https://api.crossref.org/works/10.1377/HLTHAFF.2009.0439